metabolic research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
== Description == Senna occidentalis is a foetid shrub that typically grows to a height of 1–2 m (3 ft 3 in – 6 ft 7 in) and has softly-hairy branches and stems. Its leaves are pinnate, 150–170 mm (5.9–6.7 in) long on a petiole 20–40 mm (0.79–1.57 in) long, with three to seven pairs of broadly elliptic to egg-shaped leaflets 50–70 mm (2.0–2.8 in) long and 30–40 mm (1.2–1.6 in) wide, spaced 15–30 mm (0.59–1.18 in) apart. There is a sessile glands near the base of the petiole. The flowers are yellow and arranged on the ends of branchlets and in upper leaf axils in groups of two to four on a peduncle 2–5 mm (0.079–0.197 in) long, each flower on a pedicel 10–15 mm (0.39–0.59 in) long. The petals are up to 10 mm (0.39 in) long and there are six fertile stamens, the anthers varying in length from 4 to 6 mm (0.16 to 0.24 in) long, and four staminodes. Flowering occurs all year, and the fruit is a cylindrical pod 120–180 mm (4.7–7.1 in) long, about 3 mm (0.12 in) wide and slightly curved.
Neurofibrillary tangles in Alzheimer's disease Lewy body in Parkinson's disease Pick bodies in Pick's disease Inclusions in motor neuron disease and Huntington's disease Mallory bodies in alcoholic liver disease Rosenthal fibers in astrocytes
==== Slavery in the modern era ==== Brass, Tom; van der Linden, Marcel (1997). Free and unfree labour: the debate continues. Peter Lang. ISBN 978-3-906756-87-5. Brass, Tom (2015). Towards a Comparative Political Economy of Unfree Labour: Case Studies and Debates. Taylor & Francis. ISBN 978-1-317-82735-1. Bales, Kevin, ed. (2005). Understanding Global Slavery: A Reader. University of California Press. ISBN 978-0-520-93207-4. Bales, Kevin (2007). Ending Slavery: How We Free Today's Slaves. University of California Press. ISBN 978-0-520-25470-1. Craig, Gary (2007). Contemporary Slavery in the UK: Overview and Key Issues (PDF). York: Joseph Rowntree Foundation. ISBN 978-1-85935-573-2. Archived from the original (PDF) on June 14, 2007. Retrieved December 17, 2007. Hawk, David R. (2012). The Hidden Gulag: The Lives and Voices of "those Who Are Sent to the Mountains" (PDF). Washington, DC: U.S. Committee for Human Rights in North Korea. ISBN 978-0-615-62367-2. Archived from the original (PDF) on March 13, 2015. Retrieved September 21, 2012. Nazer, Mende; Lewis, Damien (2009). Slave: My True Story. PublicAffairs. ISBN 978-0-7867-3897-7. Sage, Jesse (2015). Enslaved: True Stories of Modern Day Slavery. St. Martin's Press. ISBN 978-1-250-08310-4. Sowell, Thomas (2010). "The Real History of Slavery". Black Rednecks and White Liberals. ReadHowYouWant.com. ISBN 978-1-4596-0221-2.
There are various reasons for replacing lost bone tissue and encouraging natural bone growth, and each technique tackles jawbone defects differently. Reasons that bone grafting might be needed include sinus augmentation, socket preservation, ridge augmentation, or regeneration. There is currently some evidence supporting the use of autologous platelet concentrates (cell fragments containing growth factors to promote tissue regeneration) when bone grafting is used to treat gum disease.
Sources: en.wikipedia.org
She cuts ties with Otto and brings Eric out of retirement to launch SternTao, targeting fintech company Tender. After a one-night stand with Tender CFO Whitney Halberstram, Harper is tipped off by journalist James Dycker that Tender is concealing misconduct. She hires Sweetpea and Kwabena Bannerman—her former colleague and casual partner—and sends them to Accra to investigate Tender’s acquisitions, where they uncover falsified profits and recycled revenue. Harper presents the findings at an investment conference, causing Tender’s stock to fall 28%. During this period, she learns her estranged mother has died and struggles to grieve amid her work. Eric later transfers his ownership stake in SternTao to her and withdraws from the partnership without explanation, having been blackmailed, leaving Harper devastated. She reconciles with Yasmin after helping circulate claims that the Labour government suppressed concerns about Tender, prompting investigations and a new audit. The Tender short ultimately earns SternTao £110 million, and Harper, Sweetpea, and Kwabena scout a new office. In Paris, Harper attends a fundraiser hosted by Yasmin for Reform MP Sebastian Stefanowicz and is disturbed by the guests (including the Nazi-sympathizing Bauer family) and Yasmin's use of escorts; Yasmin shows her a compromising recording of Eric with an underage prostitute, leaving Harper shaken. She later reflects on the Tender short in an interview with journalist Patrick Radden Keefe and ponders her future.
D-dimer (or D dimer) is a dimer that is a fibrin degradation product (FDP), a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. It is so named because it contains two D fragments of the fibrin protein joined by a cross-link, hence forming a protein dimer. D-dimer concentration may be determined by a blood test to help diagnose thrombosis. Since its introduction in the 1990s, it has become an important test performed in people with suspected thrombotic disorders, such as venous thromboembolism. While a negative result practically rules out thrombosis, a positive result can indicate thrombosis but does not exclude other potential causes. Its main use, therefore, is to exclude thromboembolic disease where the probability is low. D-dimer levels are used as a predictive biomarker for the blood disorder disseminated intravascular coagulation and in the coagulation disorders associated with COVID-19 infection. A four-fold increase in the protein is an indicator of poor prognosis in people hospitalized with COVID-19.
=== Other Valve games === Valve developed several games using the GoldSrc engine, many of which were based on original user-made modifications. Valve's Team Fortress Classic, released in 1999, was developed primarily by two of the developers of the Quake mod Team Fortress. Counter-Strike and Day of Defeat were also originally Half-Life modifications that Valve purchased the rights to and re-released as standalone titles. Counter-Strike evolved into its own series with the debut of the Japanese arcade game Counter-Strike Neo in 2003 and Valve's own follow-up in 2004, Counter-Strike: Condition Zero, both of which run on the GoldSrc engine. Although Valve's further installments in the series starting with Counter-Strike: Source use the newer Source engine instead, Counter-Strike Online and Counter-Strike Nexon, two spinoff titles released by Nexon in 2008 and 2014 respectively, use GoldSrc as their basis.
Sources: en.wikipedia.org
Throughout Libya, crowds of supporters arrived at public events where he appeared. Described as "spontaneous demonstrations" by the government, groups were often coerced or paid to attend. He was typically late to public events, sometimes failing to arrive. Although Bianco thought he had a "gift for oratory", he was considered a poor orator by Blundy and Lycett. The biographer Daniel Kawczynski noted that Gaddafi was famed for his "lengthy, wandering" speeches, which typically involved criticizing Israel and the US. The journalist Ruth First called his speeches "an inexhaustible flow; didactic, at times incoherent; peppered with snatches of half-formed opinions; admonitions; confidences; some sound common sense, and as much prejudice".
=== In vitro approaches === Intrinsically unfolded proteins, once purified, can be identified by various experimental methods. The primary method to obtain information on disordered regions of a protein is NMR spectroscopy. The lack of electron density in X-ray crystallographic studies may also be a sign of disorder. Folded proteins have a high density (partial specific volume of 0.72-0.74 mL/g) and commensurately small radius of gyration. Hence, unfolded proteins can be detected by methods that are sensitive to molecular size, density or hydrodynamic drag, such as size exclusion chromatography, analytical ultracentrifugation, small angle X-ray scattering (SAXS), and measurements of the diffusion constant. Unfolded proteins are also characterized by their lack of secondary structure, as assessed by far-UV (170–250 nm) circular dichroism (esp. a pronounced minimum at ~200 nm) or infrared spectroscopy. Unfolded proteins also have exposed backbone peptide groups exposed to solvent, so that they are readily cleaved by proteases, undergo rapid hydrogen-deuterium exchange and exhibit a small dispersion (<1 ppm) in their 1H amide chemical shifts as measured by NMR. (Folded proteins typically show dispersions as large as 5 ppm for the amide protons.) Recently, new methods including fast parallel proteolysis (FASTpp) have been introduced, which allow to determine the fraction folded/disordered without the need for purification.
== Age and breed prevalence == PPID has been diagnosed in horses as young as 7 years old, although most horses are first diagnosed at ages 19 to 20. An estimated 21% of horses older than 15 years have PPID. All breeds may develop PPID, but pony breeds and Morgans seem to be more commonly affected.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.